18:19:38 EDT Sun 27 Apr 2025
Enter Symbol
or Name
USA
CA



Preveceutical Medical Inc
Symbol PREV
Shares Issued 543,703,359
Close 2025-01-24 C$ 0.025
Market Cap C$ 13,592,584
Recent Sedar Documents

Preveceutical Medical arranges $300,000 unit financing

2025-01-24 17:42 ET - News Release

Mr. Stephen Van Deventer reports

PREVECEUTICAL ANNOUNCES NON-BROKERED PRIVATE PLACEMENT

Preveceutical Medical Inc. has arranged a non-brokered private placement of up to 10 million units in the capital of the company at a price of three cents per unit for gross proceeds of up to $300,000. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of five cents per warrant share for a period of 24 months from the closing of the offering, provided that the expiry of the warrants can be accelerated if the closing price of the company's common shares on the Canadian Securities Exchange (CSE) is eight cents or greater for a minimum of 10 consecutive trading days, and a notice of acceleration is provided in accordance with the terms of the warrants.

No finders' fees are expected to be paid in connection with the offering. The company intends to use the aggregate gross proceeds from the sale of the offering to pay outstanding payables, for operating expenses and for general working capital purposes.

All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE.

About Preveceutical Medical Inc.

Preveceutical is a health science company that develops innovative options for preventive and curative therapies, utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences, and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; nature identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.

© 2025 Canjex Publishing Ltd. All rights reserved.